Cargando…

How I treat metastatic triple-negative breast cancer

Triple-negative breast cancer (TNBC) is associated with a high risk of recurrence and generally a bad prognosis. More than one-third of patients with TNBC will present distant metastases during the course of their disease. Although chemotherapy has been the main treatment option for metastatic TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caparica, Rafael, Lambertini, Matteo, de Azambuja, Evandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555596/ https://www.ncbi.nlm.nih.gov/pubmed/31231572 http://dx.doi.org/10.1136/esmoopen-2019-000504

Ejemplares similares

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
por: Caparica, Rafael, et al.
Publicado: (2019)

Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?
por: Franzoi, Maria Alice, et al.
Publicado: (2020)

Controversies in Oncology: Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?
por: Poggio, Francesca, et al.
Publicado: (2018)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis
por: Agostinetto, E., et al.
Publicado: (2021)

Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis
por: Poggio, Francesca, et al.
Publicado: (2018)

Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
por: Agostinetto, Elisa, et al.
Publicado: (2023)

Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?
por: Lambertini, Matteo, et al.
Publicado: (2018)

Oncofertility counselling in premenopausal women with HER2-positive breast cancer
por: Lambertini, Matteo, et al.
Publicado: (2019)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

How we treat patients with metastatic HER2-positive breast cancer
por: Nader-Marta, G., et al.
Publicado: (2022)

Targeting triple-negative breast cancer: A clinical perspective
por: POPOVIC, LAZAR S., et al.
Publicado: (2023)

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
por: Mehanna, Joe, et al.
Publicado: (2019)

Twenty years of anti-HER2 therapy-associated cardiotoxicity
por: Pondé, Noam F, et al.
Publicado: (2016)

How I treat endocrine-dependent metastatic breast cancer
por: Gombos, A., et al.
Publicado: (2023)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors
por: Brandão, M, et al.
Publicado: (2019)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Emerging treatment strategies for metastatic triple-negative breast cancer
por: Huppert, Laura A., et al.
Publicado: (2022)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis
por: Brandão, Mariana, et al.
Publicado: (2020)

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
por: Zeichner, Simon B., et al.
Publicado: (2016)

Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
por: Caparica, R., et al.
Publicado: (2021)

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
por: Cazzaniga, M. E., et al.
Publicado: (2017)

How shall we treat locally advanced triple negative breast cancer?
por: Luz, Paulo, et al.
Publicado: (2020)

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial
por: Lambertini, Matteo, et al.
Publicado: (2020)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
por: Mancini, Patrizia, et al.
Publicado: (2014)

Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer
por: Fertal, Shelby A., et al.
Publicado: (2022)

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
por: Pauls, Mehrnoosh, et al.
Publicado: (2022)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
por: Capici, Serena, et al.
Publicado: (2022)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Treatment options for patients with triple-negative breast cancer
por: Santana-Davila, Rafael, et al.
Publicado: (2010)

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis
por: Caparica, Rafael, et al.
Publicado: (2021)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
por: Li, Shuanghe, et al.
Publicado: (2022)

Systemic Therapy for Metastatic Triple Negative Breast Cancer: Current Treatments and Future Directions
por: Morrison, Laura, et al.
Publicado: (2023)

How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment
por: Saraiva, Diana P, et al.
Publicado: (2017)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dmqdt1dp5qq6fusq5vlaig0asd